Evelo Biosciences (NASDAQ:EVLO – Get Free Report) is projected to announce its resultson Monday, August 10th. Analysts expect Evelo Biosciences to announce earnings of ($10.1333) per share for the quarter.
Evelo Biosciences Stock Performance
Shares of EVLO stock opened at $0.00 on Friday. The stock has a market capitalization of $1,884.00, a price-to-earnings ratio of -0.00 and a beta of 1.78. Evelo Biosciences has a one year low of $0.00 and a one year high of $0.00.
About Evelo Biosciences
Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications.
Featured Stories
- Five stocks we like better than Evelo Biosciences
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
